An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.

Front Oncol · 2023 · PMC9913265 · PMID 36776307

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The JAK2 V617F VAF showed a trend of rapid decrease with treatment from 59.7% at baseline to 42.4% at Month 3, and 37.1% at Month 6.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.